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As a transmembrane glycoprotein, the epithelial cell adhesion molecule (EpCAM) 
has been shown to be strongly overexpressed on the majority of tumor cells of 
epithelial origin and its overexpression has been supposed to support tumor 
progression and metastasis. Hence EpCAM has been made as a suitable antigen for 
targeted cancer therapy. In this case different types of antibodies including antibody 
fragments such as single chain fragment variable (ScFv) antibodies have been 
produced for drug delivery to this specific antigen. Pichia pastoris is a highly 
efficient and cost-effective system for expression of recombinant proteins. In this 
study, we used the Pichia expression system to express a ScFv against EpCAM 
extracellular domain (EpEX). 
Materials and Methods: A codon optimized gene encoding anti-EpEX protein was 
cloned into the XhoI and XbaI sites of the pPICZαB vector. Transformation of 
CS115 strain was performed via electroporation method. The recombinant protein 
was linearized by using SacI restriction endonuclease prior to gene integration into 
the genome. 
Results: Successfully cloned anti- EpEX gene into the pPICZαB vector was 
confirmed by restriction analysis and sequencing. The transforming agents with 
genome containing inserted pPICZαB- anti- EpEX were confirmed via PCR 
amplification of genomic DNA using AOX1 primers. 
Conclusion: These findings imply that the engineered strain is able to express the 
recombinant anti- EpEX which may be used as a potential candidate in cancer 
immunotherapy. 
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